BBIN - ETF AI Analysis
Top Page
JPMorgan BetaBuilders International Equity ETF (BBIN)
Rating:66Neutral
Price Target:―
Positive Factors
Low Expense Ratio
The ETF charges a very low fee, which helps investors keep more of the fund’s returns over time.
Broad International Diversification
Holdings spread across many countries such as Japan, the UK, and several European and Asia-Pacific markets help reduce the impact of problems in any single region.
Strong Year-to-Date Performance with Leading Holdings
The fund has delivered strong year-to-date results, supported by well-known companies like ASML, HSBC, Novartis, and others that have generally been performing well.
Negative Factors
Recent Short-Term Weakness
The ETF has shown weak performance over the last month, which may signal short-term volatility or a pause in its upward trend.
Country Concentration in Japan
A large portion of the portfolio is invested in Japan, which increases the fund’s sensitivity to economic and market conditions in that single country.
Mixed Performance Among Top Holdings
Some major positions, such as AstraZeneca and Toyota, have been lagging this year, which can drag on overall fund performance if the weakness continues.
BBIN vs. SPDR S&P 500 ETF (SPY)
AUM6.58B
RegionDeveloped Markets
Expense Ratio0.07%
Beta0.75
IssuerJPMorgan
Inception DateDec 03, 2019
Dividend Yield3.52%
Asset ClassEquity
Index TrackedMorningstar Developed Markets ex-North America Target Market Exposure Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume219,245
30 Day Avg. Volume134,888
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
91.81Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering616
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBIN Summary
BBIN, the JPMorgan BetaBuilders International Equity ETF, tracks the Morningstar Developed Markets ex-North America Target Market Exposure Index, giving you broad exposure to stocks from countries like Japan, the UK, and Europe (but mostly outside the U.S.). It owns many well-known companies such as Nestlé and Toyota, across sectors like finance, industrials, and health care. An investor might choose BBIN to diversify a U.S.-heavy portfolio and tap into long-term growth in developed markets overseas. A key risk is that international stock prices can rise or fall with global economic and currency swings.
How much will it cost me?The JPMorgan BetaBuilders International Equity ETF (BBIN) has an expense ratio of 0.07%, meaning you’ll pay $0.70 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically has lower costs than actively managed funds.
What would affect this ETF?Positive drivers for BBIN could include economic growth in developed markets outside North America, which may boost the performance of its top holdings like ASML, Nestlé, and Toyota. However, negative factors such as rising interest rates or geopolitical tensions in Europe or Asia could impact sectors like Financials and Industrials, which have significant weight in the ETF. Additionally, regulatory changes in these regions could affect the profitability of key companies in the portfolio.
BBIN Top 10 Holdings
BBIN leans heavily on a mix of European health care and financial giants, with ASML acting as a key growth engine thanks to its rising longer-term trend despite some recent wobbling. Big banks like HSBC and Mitsubishi UFJ are steadily pulling their weight, giving the fund a lift as global rates and credit conditions support their momentum. On the defensive side, staples leader Nestlé has been losing a bit of steam, while AstraZeneca’s weaker stretch has slightly dulled the health care shine. Overall, it’s a diversified play on developed markets outside North America, rather than a single-sector or single-country bet.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.02% | $198.67M | €572.60B | 143.26% | 76 Outperform | |
| HSBC Holdings | 1.59% | $104.44M | £262.77B | 60.76% | 80 Outperform | |
| Roche Holding AG | 1.41% | $92.56M | $361.51B | 51.16% | 73 Outperform | |
| Novartis AG | 1.33% | $87.65M | CHF230.61B | 32.06% | 80 Outperform | |
| Mitsubishi UFJ Financial Group | 1.14% | $74.87M | ¥39.85T | 52.16% | 76 Outperform | |
| Nestlé SA | 1.12% | $73.55M | CHF208.89B | 10.64% | 71 Outperform | |
| AstraZeneca | 1.12% | $73.41M | $249.26B | 8.64% | 80 Outperform | |
| Shell (UK) | 1.10% | $72.24M | £181.34B | 24.71% | 73 Outperform | |
| Siemens | 1.03% | $67.98M | €213.28B | 22.18% | 74 Outperform | |
| BHP Group Ltd | 1.02% | $67.33M | AU$319.93B | 76.56% | 68 Neutral |
BBIN Technical Analysis
Positive
―
Price Trends
78.41
Positive
76.94
Positive
74.70
Positive
Market Momentum
0.96
Negative
66.19
Neutral
87.10
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBIN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 79.39, equal to the 50-day MA of 78.41, and equal to the 200-day MA of 74.70, indicating a bullish trend. The MACD of 0.96 indicates Negative momentum. The RSI at 66.19 is Neutral, neither overbought nor oversold. The STOCH value of 87.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIN.
BBIN Peer Comparison
Comparison Results
Performance Comparison
BBIN
JPMorgan BetaBuilders International Equity ETF
81.58
15.03
22.58%
DBEF
Xtrackers MSCI EAFE Hedged Equity ETF
―
―
―
EFAV
iShares MSCI EAFE Min Vol Factor ETF
―
―
―
IHDG
WisdomTree International Hedged Quality Dividend Growth Fund
―
―
―
HFXI
IQ 50 Percent Hedged FTSE International ETF
―
―
―
DDWM
WisdomTree Dynamic Currency Hedged International Equity Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents